Skip to content
OpenCapital
Get started

Twist Bioscience Corporation TWST Reportable Segment — Research and development expenses

Similar metrics at other companies

Dolby Laboratories, Inc. logo
DLBReportable Segment — R&D
$53.84M+2.2%
Snowflake logo
SNOWReportable Segment — R&D
$534.94M+13.2%
Guardant Health logo
GHReportable Segment — Research and development expense
$76.59M+2.3%
Adobe logo
ADBEReportable Segment — Research and Development, Significant Segment Expense
$911M+9.2%
Open Text logo
OTEXReportable Segment — Adjusted research and development
$168.38M-12.6%
Indivior Pharmaceuticals, Inc. logo
INDVReportable Segment — R&D
$16M-27.3%

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$5.45B+24.4%

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept twst:ResearchAndDevelopmentExpenseExcludingDepreciationAmortizationAndShareBasedCompensationExpense.

The official record: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Twist Bioscience Corporation's reportable segment — research and development expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Twist Bioscience Corporation's reportable segment — research and development expenses?
Twist Bioscience Corporation (TWST) reported reportable segment — research and development expenses of $17.37M in Q1 2026.
How has Twist Bioscience Corporation's reportable segment — research and development expenses changed year-over-year?
Twist Bioscience Corporation's reportable segment — research and development expenses decreased by 13.0% year-over-year, from $19.95M to $17.37M.
What does reportable segment — research and development expenses mean?
Captures the costs incurred by the reportable segment to discover and develop new technologies, products, or processes. This investment is critical for maintaining long-term competitive advantage and innovation within the company's specific industry.